[1] HOSACK T, DAMRY D, BISWAS S.Drug-Induced Liver Injury: a Comprehensive Review[J]. Therap Adv Gastroenterol, 2023, 16: 17562848231163410. [2] ZHU RR, XIE ZQ, MA RP.Research Status of Drug-Induced Liver Injury[J]. Journal of Community Medicine(社区医学杂志), 2023, 21(10): 535-539. [3] FU S, WU D, JIANG W, et al.Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives[J]. Front Pharmacol, 2020, 10: 1667. [4] Chinese Society of General Practice. Guideline for Primary Care Diagnosis and Management of Drug-Induced Liver Injury in China (2024)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2024, 23(2): 113-126. [5] LIU RJ, XIN XJ.Progress in Mechanism, Risk Factors, Monitoring and Rechallenge of Drug-Induced Liver Injury[J]. Chinese Journal of Clinical Hepatology(临床肝胆病杂志), 2023, 39(4): 968-973. [6] Tuberculosis Society, Chinese Medical Association.Guidelines for the Diagnosis and Treatment of Anti-Tuberculosis Drug-Induced Liver Injury (2024 Edition)[J]. Journal of Tuberculosis and Lung Diseases(结核与肺部疾病杂志), 2025, 6(2): 128-134. [7] MOOSA MS, MAARTENS G, GUNTER H, et al.A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-Tuberculosis Drug-Induced Liver Injury[J]. Clin Infect Dis, 2021, 73(9): e3377-e3383. [8] GOLDBERG DS, FORDE KA, CARBONARI DM, et al.Population-Representative Incidence of Drug-Induced Acute Liver Failure Based on an Analysis of an Integrated Health Care System[J]. Gastroen-terology, 2015, 148(7): 1353-1361. [9] MA X, CHEN Z, AN J, et al.Clinical Features and Risk Factors for Drug-Induced Liver Injury: a Retrospective Study from China[J]. Clin Ther, 2024, 46(8): 597-603. [10] LIU J, HUANG R, ZHANG J, et al.Clinical Characteristics and Prognosis of 222 Patients with Anti-Tuberculosis Drug-Induced Liver Injury[J]. China Pharmaceuticals(中国药业), 2022, 31(23): 57-61. [11] CHEN H, LIANG J, ZHAO W, et al.Analysis of Clinical Characteristics and Risk Factors for Liver Injury Induced by Atypical Antipsychotic Drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2025, 22(4): 410-414. [12] GEORGE N, CHEN M, YUEN N, et al.Interplay of Gender, Age and Drug Properties on Reporting Frequency of Drug-Induced Liver Injury[J]. Regul Toxicol Pharmacol, 2018, 94: 101-107. [13] SUZUKI A, CHEN MJ.Epidemiology and Risk Determinants of Drug-Induced Liver Injury: Current Knowledge and Future Research Needs[J]. Liver Int, 2025, 45(4): e16146. [14] MOULTON VR.Sex Hormones in Acquired Immunity and Autoimmune Disease[J]. Front Immunol, 2018, 9: 2279. [15] YUAN Y, SHIMIZU I, SHEN M, et al.Effects of Estradiol and Progesterone on the Proinflammatory Cytokine Production by Monon-uclear Cells from Patients with Chronic Hepatitis C[J]. World J Gastroenterol, 2008, 14(14): 2200-2207. [16] CROSS FS, LONG MW, BANNER AS, et al.Rifampin-Isoniazid Therapy of Alcoholic and Nonalcoholic Tuberculous Patients in a U.S. Public Health Service Cooperative Therapy Trial[J]. Am Rev Respir Dis, 1980, 122: 349-353. [17] PATEL PA, VOIGT MD.Prevalence and Interaction of Hepatitis B and Latent Tuberculosis in Vietnamese Immigrants to the United States[J]. Am J Gastroenterol, 2002, 97: 1198-1203. [18] YOU YY, REN PF, CHEN YF.Risk Factors of Drug-Induced Liver Injury in Newly Treated Pulmonary Tuberculosis Patients[J]. Henan Medical Research(河南医学研究), 2020, 29(7): 1173-1176. [19] ZHANG YH, HU T, WANG Z, et al.Predictive Value of Serum Prealbumin, Total Bilirubin, and Prothrombin Activity on Liver Injury Induced by Targeted Drugs Combined with Transcatheter Arterial Chemoembolization for Primary Liver Cancer[J]. Clinical Journal of Military Medicine(临床军医杂志), 2024, 52(7): 706-708. |